{"id":10283,"date":"2026-05-22T17:03:00","date_gmt":"2026-05-22T15:03:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=2c6fb0651b9d921f4e71a00c908ddbb6"},"modified":"2026-05-22T17:03:00","modified_gmt":"2026-05-22T15:03:00","slug":"clearnote-health-to-present-early-detection-validation-data-for-avantect-pancreatic-cancer-test-at-2026-asco-annual-meeting","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=10283","title":{"rendered":"ClearNote Health to Present Early Detection Validation Data for Avantect\u00ae Pancreatic Cancer Test at 2026 ASCO Annual Meeting"},"content":{"rendered":"

SAN DIEGO--(BUSINESS WIRE)--#5hmC<\/a>--ClearNote Health<\/a>, a company dedicated to improving early detection for some of the deadliest cancers, today announced it will present new multi-cohort validation data for its Avantect\u00ae Pancreatic Cancer Test at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting<\/a>, taking place in Chicago May 29 \u2013 June 2.<\/p><\/a><\/a>

\nASCO attendees are invited to meet with ClearNote Health\u2019s scientific and medical leadership team, including newly appointed Chief Medical Officer Jeffrey Venstrom, MD<\/a>, and Chief Scientific Officer Samuel Levy, PhD, to discuss the company\u2019s latest clinical data, strategic commercialization progress, and vision for advancing early cancer detection.<\/p>

\n\u201cPancreatic cancer remains one of the most lethal malignancies because it is often diagnosed too late for curative intervention,\u201d said Dr. Venstrom. \u201cWe are excited to share new validation data at ASCO demonstrating the strong performance of our Avantect Pancreatic Cancer Test among individuals with elevated risk. This test complements existing diagnostic and risk assessment strategies and provides clinically actionable insights when earlier detection can make the greatest difference.\u201d<\/p>

\nDuring the 2026 ASCO Annual Meeting, ClearNote Health will present results from an independent validation cohort of 1,445 individuals with multiple risk factors, including type 2 diabetes, family history, and genetic predisposition to pancreatic cancer. In this cohort, the Avantect Pancreatic Cancer Test demonstrated industry-leading performance, achieving 82.6% overall sensitivity, 76.8% sensitivity for early-stage (Stage I\u2013II) disease, and 97.5% specificity. Two additional validation cohorts totaling 338 individuals showed consistently robust performance of Avantect in individuals enriched for new onset type 2 diabetes, further supporting its performance in clinically relevant populations with elevated risk.<\/p>

\n\u201cOur enhanced Avantect test combines a rich set of signals from epigenomic, fragmentomic, and genotyping sources in concert with glycan-specific measures into a multimodal cancer detection model. The precision of cancer detection achieved with our Avantect test is reflected in these validation results,\u201d said Dr. Levy.<\/p>

\nFeatured Presentation<\/b><\/p>

\nMulti-cohort validation of a multi-analyte liquid biopsy test for early-stage pancreatic cancer detection<\/b><\/a><\/b>Abstract \/ poster number: <\/b>4139 \/ 122\nPresenter:<\/b> Anna Bergamaschi, PhD, ClearNote Health\nSession:<\/b> Gastrointestinal Cancer\nLocation:<\/b> Hall A \u2013 Posters and Exhibits\nDate and time:<\/b> Saturday, May 30, 2026, 9:00 am \u2013 12:00 pm CDT<\/p>

\nDesigned as a simple blood test, the Avantect Pancreatic Cancer Test<\/a> is intended for patients with known genetic predispositions, a family history of pancreatic cancer, or those age 50 or older who have been newly diagnosed with type 2 diabetes. By evaluating multiple cancer-associated signals together, ClearNote Health\u2019s approach provides meaningful context for care discussions. The next-generation test is being used in the Surveillance of pAncreatic health aFter diabEtes Diagnosis (SAFE-D<\/a>) study led by the NHS in the UK \u2014 one of the world\u2019s largest projects evaluating pancreatic cancer detection in individuals with new-onset diabetes. The test is also being incorporated into the international Pancreatic Cancer Early Detection (PRECEDE<\/a>) Consortium, a global multi-center effort focused on advancing earlier diagnosis and risk-stratified screening for people with familial or genetic risk for pancreatic cancer.<\/p>

\nTo learn more about ClearNote Health\u2019s planned activities at the 2026 ASCO Annual Meeting or to schedule a meeting, please visit https:\/\/go.clearnotehealth.com\/ASCO-2026<\/a>.<\/p>

\nAbout ClearNote Health<\/b><\/p>

\nClearNote Health is a privately held company dedicated to improving early detection and monitoring for some of the deadliest forms of cancer. Developed by scientists in the Stephen Quake laboratory at Stanford University, the company\u2019s patented Virtuoso\u2122 epigenomics platform<\/a> builds on the latest advances in artificial intelligence and bioinformatics to measure active biological differences between cancer and healthy cells in a blood sample. The highly sensitive, noninvasive Avantect\u00ae pancreatic<\/a> and ovarian<\/a> tests may identify cancers in high-risk patient populations earlier than conventional approaches, when patients may be more likely to benefit from treatment. The company\u2019s multi-cancer detection test was recently selected as one of two blood-based technologies for the National Cancer Institute\u2019s Vanguard Study<\/a>. ClearNote Health\u2019s headquarters and CLIA-certified, CAP-accredited, and New York State Department of Health-approved laboratory are located in San Diego. For more information, visit www.clearnotehealth.com<\/a> or follow the company on LinkedIn<\/a>.<\/p>

\nClearNote Health, the ClearNote Health logo, and Avantect are registered trademarks of ClearNote Health.<\/i><\/p> Contacts<\/b>

\nMedia Contact<\/b>Andrew Noble\n415-722-2129\nandrew@bioscribe.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"

SAN DIEGO–(BUSINESS WIRE)–#5hmC–ClearNote Health, a company dedicated to improving early detection for some of the deadliest cancers, today announced it will present new multi-cohort validation data for its Avantect\u00ae Pancreatic Cancer Test at the 20…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-10283","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/10283","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=10283"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/10283\/revisions"}],"predecessor-version":[{"id":10284,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/10283\/revisions\/10284"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=10283"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=10283"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=10283"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}